NONOF News and Press, Novo-Nordisk A/S From 02/23/24

2024-02-23 12:31:39 ET Summary Prothena Corporation plc has an update coming on the phase 1 study using PRX012 for the treatment of patients with Alzheimer's Disease, expected in 2024. Company is already in the process of exploring the use of PRX012 for the treatment of patients w...

2024-02-23 05:15:00 ET Summary Polen Capital is a high-conviction growth investment manager. We scour the globe in search of the highest quality, sustainable companies to invest in. The Global Growth Composite Portfolio outperformed the MSCI ACWI Index for the fourth quarter and t...

2024-02-22 21:01:24 ET Summary Novo Nordisk had a near perfect FY23. Fundamentally, FY24 should look quite similar. In reviewing FY23 results and commentary, we discuss key points like SELECT outcomes; CagriSema progress; and expansion into cardiovascular disease. Though expen...

2024-02-21 11:26:20 ET More on Ventyx Biosciences Ventyx: Too Risky Right Now After Some Poor Data Seeking Alpha’s Quant Rating on Ventyx Biosciences Historical earnings data for Ventyx Biosciences Financial information for Ventyx Biosciences ...

2024-02-20 15:45:00 ET Summary Eli Lilly's stock has seen a parabolic rise, with recent gains driven by retail buying, a surge in call option demand, and short covering, taking valuations to extreme levels. The stock is trading at 83x earnings, which is 4.2x the average of the res...

2024-02-20 11:00:28 ET Summary Healthcare stocks have seen a better 2024 so far this year than the entire 2023 and 2022 years combined. If you go back 2 calendar years, the broad-based Health Care Select Sector SPDR® Fund ETF was still down slightly on a total-return basis. B...

2024-02-16 07:15:34 ET More on Eli Lilly Eli Lilly: Very Strong Fundamentals, But Market Is Euphoric Eli Lilly: Overvaluation Is A Big Red Flag Will Eli Lilly and Company Become A Trillion-Dollar Baby? Eli Lilly obesity therapy tirzepatide being rolled out in...

2024-02-15 02:45:18 ET Summary Novo Nordisk's weight loss drug, Wegovy, shows potential for reducing cardiovascular risks by 20% in overweight or obese individuals. The company is actively working to scale up production of Wegovy to meet increasing demand and decrease cost per uni...

2024-02-14 17:35:57 ET Summary Novo Nordisk reported great results for fiscal 2023 with the top and bottom line growing in the higher double-digits. Growth was especially driven by Wegovy and Ozempic, and management is also optimistic for fiscal 2024. Novo Nordisk is trading f...

2024-02-13 13:07:35 ET More on Eli Lilly Will Eli Lilly and Company Become A Trillion-Dollar Baby? Eli Lilly and Company: Even 'Miracle Drugs' Can't Keep Stock Rising (Downgrade) Eli Lilly and Co (LLY) Q4 2023 Earnings Conference Call Transcript Federal judge...